# Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

> **NCT04790474** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 61 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** ixazomib-pomalidomide-dexamethasone

## Key facts

- **NCT ID:** NCT04790474
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-25
- **Primary completion:** 2026-03-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790474, "Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04790474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*